Home

Salarius Pharmaceuticals, Inc. - Common Stock (SLRX)

2.1900
+0.0600 (2.82%)

Salarius Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative therapies for cancer patients

The company specializes in the research and development of novel drug candidates that target specific epigenetic mechanisms to combat various forms of cancer. By harnessing the potential of these targeted therapies, Salarius aims to improve treatment outcomes and minimize side effects for patients. The company's approach emphasizes precision medicine, with a commitment to addressing unmet medical needs in oncology through robust scientific innovation and clinical trials.

SummaryNewsPress ReleasesChartHistoricalFAQ
Shareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders
Ademi LLP is investigating Salarius (NASDAQSLRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Decoy Therapeutics.
By Ademi LLP · Via Business Wire · January 13, 2025